Vascodagama Online Journal

Meningioma Market to Witness Growth by 2032, Estimates DelveInsight | Companies – Ariad Pharmaceutics, Clarity Pharmaceuticals, Actuate Therapeutics, Abbvie and others.

 Breaking News
  • No posts were found

Meningioma Market to Witness Growth by 2032, Estimates DelveInsight | Companies – Ariad Pharmaceutics, Clarity Pharmaceuticals, Actuate Therapeutics, Abbvie and others.

March 22
05:12 2023
Meningioma Market to Witness Growth by 2032, Estimates DelveInsight | Companies - Ariad Pharmaceutics, Clarity Pharmaceuticals, Actuate Therapeutics, Abbvie and others.
Meningioma Market

DelveInsight’s “Meningioma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Meningioma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Meningioma market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Meningioma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Meningioma market.


Request for a Free Sample Report @ Meningioma Market Insight


Some facts of the Meningioma Market Report are:

  • Some of the Meningioma companies working in the market are Ariad Pharmaceutics, Clarity Pharmaceuticals, Actuate Therapeutics, Abbvie, And Many Others.
  • Emerging Meningioma therapies covered in the report are Brigatinib, SARTATE, 9-ING-41, Veliparib, And Many Others
  • Even if comparisons are made difficult due to differences in methodologies, available annual incidence rates (sex- and age-standardized, generally on the US or World standard population), provided by population-based registries range from 1.3/100,000 to 7.8/100,000 for cerebral meningiomas. An increase in the incidence of primary brain tumors in general and of meningiomas, in particular, has been observed during the past decades in several countries.
  • Atypical and malignant meningiomas comprise a small fraction of the total (~5%) and have a slight male predominance. Reported rates for Black Non-Hispanics are slightly higher (6.67) than for White Non-Hispanic and Hispanics (5.90 and 5.94, respectively).


Meningioma Overview

Meningiomas are the most common benign intracranial tumor. They originate from arachnoid cap cells, which are cells within the thin, spiderweb-like membrane that covers the brain and spinal cord. The arachnoid is one of three protective layers, collectively known as the meninges, which surround the brain and the spinal cord. The other two layers of the meninges are the dura mater and pia mater. Although the majority of meningiomas are benign, these tumors can grow slowly until they are very large, if left undiscovered, and, in some locations, can be severely disabling and life-threatening. Other forms of meningioma may be more aggressive. Most patients develop a single meningioma; however, some patients may develop several tumors growing simultaneously in other locations of the brain or spinal cord.


Learn more about Meningioma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @


Meningioma Market

The Meningioma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Meningioma market trends by analyzing the impact of current Meningioma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Meningioma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Meningioma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Meningioma market in 7MM is expected to witness a major change in the study period 2019-2032.


Request a sample and discover more about the report offerings @


Meningioma Epidemiology

The Meningioma epidemiology section provides insights into the historical and current Meningioma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Meningioma market report also provides the diagnosed patient pool, trends, and assumptions. 


Explore more about Meningioma Epidemiology @


Meningioma Drugs Uptake

This section focuses on the uptake rate of the potential Meningioma drugs recently launched in the Meningioma market or expected to be launched in 2019-2032. The analysis covers the Meningioma market uptake by drugs, patient uptake by therapies, and sales of each drug.   

Meningioma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Meningioma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Meningioma Pipeline Development Activities

The Meningioma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Meningioma key players involved in developing targeted therapeutics.


Meningioma Therapeutics Assessment

Major key companies are working proactively in the Meningioma Therapeutics market to develop novel therapies which will drive the Meningioma treatment markets in the upcoming years are are Ariad Pharmaceutics, Clarity Pharmaceuticals, Actuate Therapeutics, Abbvie, And Many Others.


Learn more about the emerging therapies & key companies @


Meningioma Report Key Insights

1. Meningioma Patient Population

2. Meningioma Market Size and Trends

3. Key Cross Competition in the Meningioma Market

4. Meningioma Market Dynamics (Key Drivers and Barriers)

5. Meningioma Market Opportunities

6. Meningioma Therapeutic Approaches

7. Meningioma Pipeline Analysis

8. Meningioma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Meningioma Market


Table of Contents

1. Key Insights

2. Executive Summary

3. Meningioma Competitive Intelligence Analysis

4. Meningioma Market Overview at a Glance

5. Meningioma Disease Background and Overview

6. Meningioma Patient Journey

7. Meningioma Epidemiology and Patient Population

8. Meningioma Treatment Algorithm, Current Treatment, and Medical Practices

9. Meningioma Unmet Needs

10. Key Endpoints of Meningioma Treatment

11. Meningioma Marketed Products

12. Meningioma Emerging Therapies

13. Meningioma Seven Major Market Analysis

14. Attribute Analysis

15. Meningioma Market Outlook (7 major markets)

16. Meningioma Access and Reimbursement Overview

17. KOL Views on the Meningioma Market

18. Meningioma Market Drivers

19. Meningioma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States